The combination of the LAG-3 monoclonal antibody Relatlimab and the anti-PD-1 antibody Nivolumab is effective in prolonging PFS and progression-free survival rate in patients with unresectable or metastatic MM [49]. Here, LAG3 is linked to Miyoshi myopathy.